Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs clopidogrel after PCI in ACS patients with severe renal insufficiency on dialysis
ChiCTR2100043135Phase 4Recruiting
- Sponsor
- Yuebei People's Hospital
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor in acute coronary syndrome (ACS), myocardial infarction (MI) and end-stage kidney disease (ESKD) (2 arms), sponsored by Yuebei People's Hospital. Primary endpoints: major adverse cardiac events and bleeding events. Started Feb 2021; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2100043135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043135.